Vor Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-117.86	-92.09	-70.13	-49.26	-12.61	Upgrade
Depreciation & Amortization	8.22	6.1	4.45	1.39	0.09	Upgrade
Share-Based Compensation	13.36	10.7	4.32	1.34	0.17	Upgrade
Other Operating Activities	-4.01	-9.85	-9.01	4.32	0.72	Upgrade
Operating Cash Flow	-100.29	-85.14	-69.14	-36.29	-9.86	Upgrade
Capital Expenditures	-1.07	-8.46	-3.89	-4.16	-0.75	Upgrade
Change in Investments	72.08	-85.63	-87.76	0	0	Upgrade
Investing Cash Flow	71.01	-94.09	-91.65	-4.16	-0.75	Upgrade
Share Issuance / Repurchase	2.94	117.14	187.54	0.26	0.01	Upgrade
Other Financing Activities	-	-	45.38	82.27	17.69	Upgrade
Financing Cash Flow	2.94	117.14	232.91	82.53	17.7	Upgrade
Net Cash Flow	-26.35	-62.1	72.12	42.07	7.1	Upgrade
Free Cash Flow	-101.36	-93.61	-73.04	-40.45	-10.6	Upgrade
Free Cash Flow Per Share	-1.51	-2.37	-2.19	-189.34	-6.78	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).